OR WAIT null SECS
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
Activation and expansion are essential for success in both autologous and allogeneic therapies.
Continuous manufacturing and a quality-by-design development approach are a natural fit.
February 03, 2021
New approaches to clinical trials, spurred by the COVID-19 pandemic, have dramatically shortened development timeframes. Can these gains be sustained once conditions return to normal?
Plasma-based proteins and cell-based therapies have significant potential to address unmet medical needs.
Rapid growth in biologics and increasing complexity of new compounds are some of the factors driving development of innovative delivery solutions.
Advanced manufacturing technologies are available, but challenges need to be addressed.
Viewpoint: Continued dialogue among pharma stakeholders is needed to achieve consensus regarding excipient composition.
February 02, 2021
Outsourcing partners can provide a multitude of advantages in the development of drug delivery solutions, including those designed for targeted patient populations.
Open communication and transparency coupled with technical expertise foster strong long-term manufacturing partnerships.
Collaboration between equipment suppliers and users is leading to innovation and optimization in biopharmaceutical manufacturing.
January 28, 2021
The launch of HiScreen Fibro PrismA, the company’s newest product for early mAb purification process development strengthens Cytiva’s new fiber-based Protein A platform.
January 19, 2021
The new US offices will give the company the ability to support its US-based customers on site while continuing to collaborate with its global team.